Illumina, Ovation.io launching first-of-kind GLP-1 dataset

Illumina (ILMN) and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1, or GLP-1, receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery and development. One in eight adults in the United States have used a GLP-1 receptor agonist, according to a 2024 health tracking poll. However, roughly 40% of users with Type 2 diabetes do not respond effectively to GLP-1 receptor agonists. The collaboration aims to accelerate GLP-1 therapy development, indication expansion research, and discovery of novel biomarkers and drug targets in nonresponsive populations. Through a multiyear agreement, Illumina and Ovation are launching an integrated dataset of phenotypic, genomic, and proteomic data from patients treated with GLP-1 therapies, including therapy-responsive and nonresponsive populations. The companies plan to explore opportunities to scale the GLP-1 dataset and generate others in the future.